However, when fused to GM-CSF, IL-2, or IL-4, these recombinant molecules elicited anti-tumor immunity when administered without carrier or adjuvant (Tao and Levy, 1993; Chen et al., 1994). The gene discussed is IL4; the disease is neoplasm.